Hobao Liu, Yan Wang, Taomin Su, Ningjia Shen, Bohao Zheng, Bin Wu, Zhuojun Liao, Jiamin Lu, Xu Chang, Jinyan Zhao, Min Li, Qingyang Meng, Sheng Shen, Xiaojian Ni, Shulong Zhang. "A phase II, exploratory trial of cadonilimab (AK104) plus gemcitabine-cisplatin (GC) as a conversion therapy for patients (pts) with unresectable or systemic treatment–failed biliary tract cancer (BTC).." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.e16177